NURIX THERAPEUTICS, INC.
July 15, 2020
Arthur T. Sands, M.D., Ph.D.
c/o Nurix Therapeutics, Inc.
RE: Continued Employment with Nurix Therapeutics, Inc.
This employment letter sets forth the terms confirms your continued employment as Chief Executive Officer of Nurix Therapeutics, Inc., a Delaware Corporation (the Company or Nurix). You will continue to report to the Board of Directors of the Company (the Board) and will remain a member of the Board. This employment letter amends and restates the employment letter entered into between you and Nurix, dated February 20, 2020 (the Prior Agreement).
a. Salary. In this position, the Company will pay you an annual base salary of $525,000 per year, payable in accordance with the Companys standard payroll schedule. Your pay will be periodically reviewed as a part of the Companys regular reviews of compensation.
b. Bonus. You will be eligible to receive a cash incentive annual bonus of up to 50% of your base salary, based upon the achievement of both Company and personal goals. Any annual bonus earned will be paid no later than March 15th of the year following the year in which such bonus was earned. Please note that bonus programs, payouts and criterion are subject to change or adjustment as the business needs at the Company may require.
c. Equity Awards. You currently hold Company equity grants. You will be eligible for future discretionary equity grants at the sole discretion of the Company.
2. Employee Benefits. You will be entitled to participate in employee benefit plans currently and hereafter maintained by the Company of general applicability to other employees of the Company subject to the eligibility requirements of each such benefit plan. The Company, in its sole discretion, may amend, suspend or terminate its employee benefits at any time, with or without notice. In addition, you will be entitled to vacation in accordance with the Companys vacation policy, as in effect from time to time. We also acknowledge that you are a participant in, or will become a participant in, the Companys Severance and Change in Control Plan (the Severance & Change in Control Plan).
3. Confidentiality Agreement. By signing this letter agreement, you reaffirm the terms and conditions of the confidential information and invention assignment agreement by and between you and the Company.
4. No Conflicting Obligations. You understand and agree that by signing this letter agreement, you represent to the Company that your performance will not breach any other agreement to which you are a party and that you have not, and will not during the term of your employment with the Company, enter into any oral or written agreement in conflict with any of the provisions of this letter or the Companys policies. You are not to bring with you to the Company, or use or disclose to any person associated with the Company, any confidential or proprietary information belonging to any former employer or other